Paradigm Biopharmaceuticals Limited
PBIGF
Other OTC0.13
USD
- -
- -
ISIN
AU000000PAR5
Return %
Stock
S&P500
1Y
-51.34
26.53
3Y
-79.54
76.60
5Y
-92.60
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Paul John Rennie
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 Collins Street Melbourne VIC Australia 3000
- IPO Date
- May 10, 2019
- Website
- paradigmbiopharma.com
- Similar Companies
- Business
- Paradigm Biopharmaceuticals Limited (ASX:PAR; OTC:PBIGF) is a late-stage clinical-stage biopharmaceutical company that discovers, develops and commercializes repurposed therapies derived from underutilized molecules to address unmet medical needs in inflammatory and degenerative diseases. The company focuses primarily on injectable pentosan polysulfate sodium (iPPS or PPS, branded Zilosul) for the treatment of knee osteoarthritis, targeting inflammation, pain and tissue regeneration in moderate-to-severe cases with disease-modifying potential; it also advances PPS formulations for mucopolysaccharidosis and other musculoskeletal disorders driven by injury, inflammation or genetic factors, including trademarks Rhinosul; additionally, it develops Pentacoxib, an oral combination of PPS and a COX-2 inhibitor, initially for veterinary osteoarthritis with plans for human applications in earlier-stage disease. Founded in 2014 and headquartered in Melbourne, Australia, with offices in the EU and US, Paradigm operates globally across key markets including the US, Australia, Canada and EU5 nations, conducting multi-site clinical trials and partnering with contract research organizations for regulatory submissions. In recent developments, the company initiated its global Phase 3 PARA_OA_012 trial for Zilosul in 2025 following US FDA protocol acceptance, activating 27 sites across Australia and the US with patient screening underway for 466 participants; it secured A$16 million in equity financing in December 2024 and a US$27 million convertible note facility with Obsidian Global Partners in July 2025 to fund the program through mid-2026 interim analysis; furthermore, it acquired Proteobioactives Pty Ltd to gain rights to Pentacoxib, broadening its osteoarthritis pipeline, while reporting 2025 revenue of A$7.1 million and a reduced net loss of A$18.8 million.